Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Linagliptin

FDA-approved product (tablet, oral), marketed as Linagliptin, Tradjenta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Linagliptin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
FDA pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Linagliptin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Linagliptin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

    NCT03337698 · start 2017-12-27

    Registered record
    Registry ID
    NCT03337698
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Atezolizumab; Cobimetinib; RO6958688; Docetaxel; CPI-444; Pemetrexed; Carboplatin; Gemcitabine; Linagliptin; Tocilizumab; Ipatasertib; Bevacizumab; Sacituzumab Govitecan; Radiation; Evolocumab; Tiragolumab; XL092; Camonsertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-12-27
    Completion
    2025-11-25
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionAtezolizumab; Cobimetinib; RO6958688; Docetaxel +14 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES

    NCT03433248 · start 2017-11-09

    Registered record
    Registry ID
    NCT03433248
    Conditions
    Type2 Diabetes
    Interventions
    EMPA/LINA 10/5 mg QD (n=22); LINA/EMPA 5/10 mg QD (N=22); Gliclazide 30 mg QD/BID (N=22)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-11-09
    Completion
    2022-09-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType2 Diabetes
    InterventionEMPA/LINA 10/5 mg QD (n=22); LINA/EMPA 5/10 mg QD (N=22); Gliclazide 30 mg QD/BID (N=22)
    PhasePhase 4
    Registry statusUnknown

  • Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

    NCT03194945 · start 2017-11-01

    Registered record
    Registry ID
    NCT03194945
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    CSII followed by Lina+MET; CSII followed by Lina; CSII followed by MET; CSII alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-11-01
    Completion
    2022-12-31
    Enrolment
    412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionCSII followed by Lina+MET; CSII followed by Lina; CSII followed by MET; CSII alone
    PhasePhase 4
    Registry statusCompleted

  • A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

    NCT03281369 · start 2017-10-13

    Registered record
    Registry ID
    NCT03281369
    Conditions
    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
    Interventions
    5-Fluorouracil (5-FU); Leucovorin; Oxaliplatin; Atezolizumab; Cobimetinib; Ramucirumab; Paclitaxel; PEGylated recombinant human hyaluronidase (PEGPH20); BL-8040; Linagliptin; Atezolizumab; Cobimetinib; Cisplatin; Tiragolumab; 5-Fluorouracil (5-FU)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-10-13
    Completion
    2025-10-09
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
    Intervention5-Fluorouracil (5-FU); Leucovorin; Oxaliplatin; Atezolizumab +11 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Replication of the CARMELINA Diabetes Trial in Healthcare Claims

    NCT03936036 · start 2017-09-22

    Registered record
    Registry ID
    NCT03936036
    Conditions
    Diabetes
    Interventions
    Linagliptin; Sulfonylurea
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-09-22
    Completion
    2021-02-18
    Enrolment
    101,830

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionLinagliptin; Sulfonylurea
    PhaseNot recorded
    Registry statusCompleted

  • Linagliptin Add-on to Insulin Background Therapy

    NCT02897349 · start 2016-09-30

    Registered record
    Registry ID
    NCT02897349
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    placebo; linagliptin; background therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-09-30
    Completion
    2019-01-18
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    Interventionplacebo; linagliptin; background therapy
    PhasePhase 3
    Registry statusCompleted

  • The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

    NCT02792400 · start 2016-05

    Registered record
    Registry ID
    NCT02792400
    Conditions
    Type 2 Diabetes
    Interventions
    LY2403021; LY2403021 placebo; Standardised liquid meal; Linagliptin; Linagliptin placebo; Empagliflozin; Empagliflozin placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-05
    Completion
    2018-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionLY2403021; LY2403021 placebo; Standardised liquid meal; Linagliptin +3 more
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

    NCT02752113 · start 2016-04

    Registered record
    Registry ID
    NCT02752113
    Conditions
    Diabetes Mellitus Type 2
    Interventions
    Empagliflozin and Linagliptin; Metformin and Insulin sc
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04
    Completion
    2019-05
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus Type 2
    InterventionEmpagliflozin and Linagliptin; Metformin and Insulin sc
    PhasePhase 3
    Registry statusCompleted

  • Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

    NCT02608177 · start 2015-11

    Registered record
    Registry ID
    NCT02608177
    Conditions
    Chronic Kidney Diseases; Type 2 Diabetes
    Interventions
    Linagliptin; Glipizide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11
    Completion
    2018-08
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Diseases; Type 2 Diabetes
    InterventionLinagliptin; Glipizide
    PhaseNot applicable
    Registry statusCompleted

  • A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

    NCT02429232 · start 2015-10

    Registered record
    Registry ID
    NCT02429232
    Conditions
    Osteoporosis; Diabetes Mellitus
    Interventions
    Pioglitazone; Linagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2017-12
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis; Diabetes Mellitus
    InterventionPioglitazone; Linagliptin
    PhasePhase 4
    Registry statusUnknown

  • Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

    NCT02453555 · start 2015-05-14

    Registered record
    Registry ID
    NCT02453555
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Linagliptin; Empagliflozin placebo + linagliptin placebo low dose; Empagliflozin + linagliptin low dose; Linagliptin placebo; Empagliflozin + linagliptin high dose; Empa + lina highdose placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05-14
    Completion
    2017-03-27
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionLinagliptin; Empagliflozin placebo + linagliptin placebo low dose; Empagliflozin + linagliptin low dose; Linagliptin placebo +2 more
    PhasePhase 3
    Registry statusCompleted

  • Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

    NCT02401880 · start 2015-05

    Registered record
    Registry ID
    NCT02401880
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Linagliptin; Placebo; Empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-05
    Completion
    2015-12
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionLinagliptin; Placebo; Empagliflozin
    PhasePhase 4
    Registry statusCompleted

  • Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus

    NCT02077309 · start 2014-08

    Registered record
    Registry ID
    NCT02077309
    Conditions
    Diabetes Mellitus Type 2 (T2DM); Vascular Inflammation; Plaque Morphology
    Interventions
    Linagliptin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2014-08
    Completion
    2015-11
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus Type 2 (T2DM); Vascular Inflammation; Plaque Morphology
    InterventionLinagliptin; Placebo
    PhasePhase 3
    Registry statusTerminated

  • The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones

    NCT02180334 · start 2014-07

    Registered record
    Registry ID
    NCT02180334
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Mosapride citrate; Linagliptin; Acetaminophen (paracetamol)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2015-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionMosapride citrate; Linagliptin; Acetaminophen (paracetamol)
    PhasePhase 4
    Registry statusCompleted

  • Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns

    NCT02138097 · start 2014-05

    Registered record
    Registry ID
    NCT02138097
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-08
    Enrolment
    615,067

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted